Wadsworth Center win puts Jacobs Solutions in focus

Jacobs Solutions (J) has moved into the spotlight after being named technical advisor on the New York State Department of Health’s planned $1.7b Wadsworth Center Public Health Laboratory in Albany.

The project consolidates multiple laboratories into a single campus and places Jacobs Solutions at the center of a long term public health infrastructure build, prompting investors to reassess how the stock reflects its exposure to health and life sciences related work.

Recent contract wins such as the Wadsworth Center role and a new desalination feasibility study in Singapore have come as Jacobs Solutions’ share price return has risen 6.41% over the past 30 days but is down 9.83% year to date. The 3 year total shareholder return of 30.50% contrasts with a 3.71% decline over the past year, suggesting longer term holders have fared better than recent buyers.

If projects like Wadsworth have you thinking about where else critical infrastructure spending could show up, it may be worth scanning 33 power grid technology and infrastructure stocks

With Jacobs Solutions’ share price up over the past month but down over the past year, and trading below some analyst and intrinsic value estimates, the key question is whether this represents a reset that opens an opportunity, or whether the market is already factoring in expectations for future growth.

Most Popular Narrative: 22.9% Undervalued

The most followed narrative currently values Jacobs Solutions at $158.27 per share, compared with a last close of $122.04, and anchors that view on long term, contracted infrastructure and digital work.

Record-high backlog growth (up 14% year-over-year) in Water, Advanced Facilities, and Critical Infrastructure, driven by global infrastructure modernization, water scarcity, and data center expansion, provides strong visibility into multi-year revenue growth and supports confidence in accelerating top-line results into FY '26 and beyond.

Read the complete narrative. Read the complete narrative.

Want to understand what underpins that gap between price and fair value for Jacobs Solutions? The narrative leans heavily on rising margins, faster earnings than revenue growth, and a richer mix of consulting and AI linked work. The specific revenue path, profit assumptions and future P/E multiple are all spelled out for you in one place.

Result: Fair Value of $158.27 (UNDERVALUED)

However, Jacobs Solutions’ reliance on government backed infrastructure spending and its exposure to complex, long duration projects could quickly test this undervaluation narrative if funding or execution wobbles.

Another View: What Jacobs Solutions’ P/E Is Telling You

While the most popular narrative sees Jacobs Solutions as 22.9% undervalued, the current P/E of 35.2x paints a tougher picture. That is higher than the US Professional Services industry at 19x, the peer average at 27x, and above a fair ratio estimate of 28.4x.

Put simply, on earnings multiples the stock carries a richer price tag than both its sector and what the fair ratio implies the market could move toward over time. This raises the question of whether you are being paid enough for that valuation risk.

Next Steps

Seen enough mixed signals around Jacobs Solutions to feel uncertain? Act while the details are fresh, examine the full context of risks and upside, and weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Jacobs Solutions?

If Jacobs Solutions has sharpened your thinking, do not stop here. Cast the net wider now or risk missing other stocks that may better fit your goals.

• Target steady compounding potential by reviewing companies with reliable payouts using the 7 dividend fortresses.
• Hunt for quality at a discount by scanning the 44 high quality undervalued stocks before the crowd pays closer attention.
• Prioritize capital preservation by focusing on companies highlighted in the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.